Minami Yagi1, Atsushi Tanaka2, Tadashi Namisaki3, Atsushi Takahashi4, Masanori Abe5, Akira Honda6, Yasushi Matsuzaki6, Hiromasa Ohira4, Hitoshi Yoshiji3, Hajime Takikawa1. 1. Department of Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8605, Japan. 2. Department of Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8605, Japan. a-tanaka@med.teikyo-u.ac.jp. 3. Third Department of Internal Medicine, Nara Medical University, Nara, Japan. 4. Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan. 5. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan. 6. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan.
Abstract
BACKGROUND: Patients with primary biliary cholangitis (PBC) frequently suffer from pruritus, which can severely impair their health-related quality of life (HRQOL). Nalfurafine hydrochloride, a selective κ-opioid receptor agonist, was recently approved in Japan for refractory pruritus in patients with chronic liver diseases, but it still remains unclear whether this treatment improves the patient-reported outcome (PRO) in PBC patients with refractory pruritus. Herein, we conducted a multicenter, post-marketing, single-arm prospective study to investigate the efficacy of nalfurafine in terms of PRO, and the associations of the efficacy with any clinical characteristics. METHODS: After screening for pruritus in 496 patients with PBC using PBC-40 and the visual analog scale (VAS), we identified 141 patients with moderate to severe pruritus; these were invited to participate in the study. The participants received 2.5 μg nalfurafine once daily for 12 weeks, and pruritus and HRQOL were assessed in week 12 of this treatment. Generic HRQOL, short form 36, blood chemistries, and serum autotaxin levels were also measured at baseline and at week 12. RESULTS: Forty-four patients participated in this study. The mean PBC-40 itch domain scores and VAS declined during the study period, from 8.56 to 7.63 (P = 0.041) and from 42.9 to 29.3 (P = 0.001) at baseline and at week 12, respectively, indicating a significant effect of nalfurafine. The other domains of PBC-40 and all domains of SF-36 were not significantly altered by this treatment. We failed to find any association between the change in VAS and PBC-40 itch scores and any clinical variable. Serum autotaxin levels were significantly increased during the study period. CONCLUSIONS: This study demonstrated that nalfurafine improved pruritus in patients with PBC, independent of their clinical characteristics, but had a limited effect on the PRO.
BACKGROUND:Patients with primary biliary cholangitis (PBC) frequently suffer from pruritus, which can severely impair their health-related quality of life (HRQOL). Nalfurafine hydrochloride, a selective κ-opioid receptor agonist, was recently approved in Japan for refractory pruritus in patients with chronic liver diseases, but it still remains unclear whether this treatment improves the patient-reported outcome (PRO) in PBC patients with refractory pruritus. Herein, we conducted a multicenter, post-marketing, single-arm prospective study to investigate the efficacy of nalfurafine in terms of PRO, and the associations of the efficacy with any clinical characteristics. METHODS: After screening for pruritus in 496 patients with PBC using PBC-40 and the visual analog scale (VAS), we identified 141 patients with moderate to severe pruritus; these were invited to participate in the study. The participants received 2.5 μg nalfurafine once daily for 12 weeks, and pruritus and HRQOL were assessed in week 12 of this treatment. Generic HRQOL, short form 36, blood chemistries, and serum autotaxin levels were also measured at baseline and at week 12. RESULTS: Forty-four patients participated in this study. The mean PBC-40 itch domain scores and VAS declined during the study period, from 8.56 to 7.63 (P = 0.041) and from 42.9 to 29.3 (P = 0.001) at baseline and at week 12, respectively, indicating a significant effect of nalfurafine. The other domains of PBC-40 and all domains of SF-36 were not significantly altered by this treatment. We failed to find any association between the change in VAS and PBC-40 itch scores and any clinical variable. Serum autotaxin levels were significantly increased during the study period. CONCLUSIONS: This study demonstrated that nalfurafine improved pruritus in patients with PBC, independent of their clinical characteristics, but had a limited effect on the PRO.
Entities:
Keywords:
Autotaxin; Health-related quality of life; Opioid; PBC-40; SF-36
Authors: Andreas E Kremer; Remco van Dijk; Pamela Leckie; Frank G Schaap; Edith M M Kuiper; Thomas Mettang; Katrin S Reiners; Ulrike Raap; Henk R van Buuren; Karel J van Erpecum; Nathan A Davies; Christian Rust; Andreas Engert; Rajiv Jalan; Ronald P J Oude Elferink; Ulrich Beuers Journal: Hepatology Date: 2012-10 Impact factor: 17.425
Authors: Ying Sun; Weici Zhang; Jilly F Evans; Annarosa Floreani; Zhengsheng Zou; Yukiko Nishio; Ruizhao Qi; Patrick S C Leung; Christopher L Bowlus; M Eric Gershwin Journal: Autoimmun Rev Date: 2016-03-24 Impact factor: 9.754
Authors: George F Mells; Greta Pells; Julia L Newton; Andrew J Bathgate; Andrew K Burroughs; Michael A Heneghan; James M Neuberger; Darren B Day; Samantha J Ducker; Richard N Sandford; Graeme J Alexander; David E J Jones Journal: Hepatology Date: 2013-07 Impact factor: 17.425